Ethan Perlstein started his company with Silicon Valley funding and a Bay Area lab, taking a traditional, centralized path to working on drug development and drug repurposing. But that was back in 2014. Today, his public benefit corporation (Perlara), looks like a very different business, made up of biotech consultants from around the world that work on guided cures for families and foundations with rare diseases. Ethan walks us through the evolution of his company through the years and how Perlara developed a drug entering a Phase 3 trial this year. Learn from Perlstein's decentralized approach to biotech in this episode.
UltraRare Bio is a web3 collective focused on scientific storytelling for the greater good. Our podcast aims to educate people about decentralized science and social impact in web3. https://www.ultrarare.bio/
Podden och tillhörande omslagsbild på den här sidan tillhör
Jocelynn Pearl. Innehållet i podden är skapat av Jocelynn Pearl och inte av,
eller tillsammans med, Poddtoppen.
